
Armistice Capital, LLC
About Armistice Capital, LLC’s 13F portfolio
Armistice Capital, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Armistice Capital, LLC reported $3.6B across 323 US-listed positions (). Its largest position is MADRIGAL PHARMACEUTICALS INC (MDGL) at 4.3% of the reported book, and its ten biggest holdings make up 27% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: MDGL MADRIGAL PHARMACEUTICALS INC | — — | 4.3% | 288K | $154.6M |
| 2 | NASDAQ: SUPN SUPERNUS PHARMACEUTICALS | — — | 3.4% | 2.6M | $123.1M |
| 3 | NASDAQ: CYTK CYTOKINETICS INC | — — | 2.8% | 1.2M | $102.3M |
| 4 | NASDAQ: INCY INCYTE CORP | — — | 2.8% | 900K | $102.0M |
| 5 | NASDAQ: NBIX NEUROCRINE BIOSCIENCES INC | — — | 2.5% | 536K | $90.3M |
| 6 | NASDAQ: TVTX TRAVERE THERAPEUTICS INC | — — | 2.5% | 1.6M | $89.3M |
| 7 | NASDAQ: AGIO AGIOS PHARMACEUTICALS INC | — — | 2.5% | 2.4M | $89.1M |
| 8 | NASDAQ: PTCT PTC THERAPEUTICS INC | — — | 2.4% | 1.1M | $87.4M |
| 9 | NYSE: UNH UNITEDHEALTH GROUP INC | — — | 2.1% | 183K | $76.1M |
| 10 | NASDAQ: FRPT FRESHPET INC | — — | 2.1% | 1.3M | $74.5M |
| 11 | NASDAQ: DYN DYNE THERAPEUTICS INC | — — | 1.9% | 3.1M | $68.6M |
| 12 | NASDAQ: AMZN AMAZON COM INC | — — | 1.9% | 285K | $67.8M |
| 13 | NASDAQ: IMVT IMMUNOVANT INC | — — | 1.9% | 1.7M | $66.9M |
| 14 | NASDAQ: RIGL RIGEL PHARMACEUTICALS INC | — — | 1.8% | 1.7M | $65.4M |
| 15 | NYSE: TMO THERMO FISHER SCIENTIFIC INC | — — | 1.7% | 122K | $61.4M |
| 16 | NASDAQ: IRWD IRONWOOD PHARMACEUTICALS INC | — — | 1.6% | 13.9M | $58.7M |
| 17 | NASDAQ: HRMY HARMONY BIOSCIENCES HLDGS IN | — — | 1.6% | 1.6M | $56.9M |
| 18 | NASDAQ: REGN REGENERON PHARMACEUTICALS | — — | 1.5% | 90K | $56.0M |
| 19 | NASDAQ: NKTR NEKTAR THERAPEUTICS | — — | 1.4% | 724K | $50.5M |
| 20 | NASDAQ: MLYS MINERALYS THERAPEUTICS INC | — — | 1.3% | 1.7M | $46.8M |
| 21 | NASDAQ: SNY SANOFI SA | — — | 1.3% | 1.1M | $45.4M |
| 22 | NASDAQ: IMCR IMMUNOCORE HLDGS PLC | — — | 1.3% | 1.4M | $45.3M |
| 23 | NASDAQ: GOOGL ALPHABET INC | — — | 1.3% | 126K | $45.2M |
| 24 | NASDAQ: SLDB SOLID BIOSCIENCES INC | — — | 1.2% | 4.3M | $42.7M |
| 25 | NASDAQ: MDB MONGODB INC | — — | 1.2% | 125K | $42.0M |
Showing 1–25 of 323 positions on this page reported in this 13F.
- Healthcare68%
- Technology15%
- Consumer Cyclical7.7%
- Communication Services4.2%
- Consumer Defensive3.2%
- Industrials1.2%
- Financial Services0.1%
- Real Estate0.1%
- Basic Materials0.1%
- Energy0.1%
- Utilities0.0%
- AddedMDGLMADRIGAL PHARMACEUTICALS INC+8.9%$154.6M
- AddedSUPNSUPERNUS PHARMACEUTICALS+39.6%$123.1M
- AddedCYTKCYTOKINETICS INC+57.1%$102.3M
- AddedINCYINCYTE CORP+37.0%$102.0M
- AddedUNHUNITEDHEALTH GROUP INC+23.6%$76.1M
- AddedFRPTFRESHPET INC+15.3%$74.5M
- AddedAMZNAMAZON COM INC+8.6%$67.8M
- AddedRIGLRIGEL PHARMACEUTICALS INC+30.6%$65.4M
- AddedTMOTHERMO FISHER SCIENTIFIC INC+33.9%$61.4M
- AddedREGNREGENERON PHARMACEUTICALS+149%$56.0M
- ReducedNBIXNEUROCRINE BIOSCIENCES INC−26.0%$90.3M
- ReducedTVTXTRAVERE THERAPEUTICS INC−67.9%$89.3M
- ReducedAGIOAGIOS PHARMACEUTICALS INC−11.6%$89.1M
- ReducedPTCTPTC THERAPEUTICS INC−48.4%$87.4M
- ReducedDYNDYNE THERAPEUTICS INC−2.8%$68.6M
- ReducedIMVTIMMUNOVANT INC−51.3%$66.9M
- ReducedIRWDIRONWOOD PHARMACEUTICALS INC−7.3%$58.7M
- ReducedHRMYHARMONY BIOSCIENCES HLDGS IN−3.7%$56.9M
- ReducedKURAKURA ONCOLOGY INC−1.6%$40.3M
- ReducedUBERUBER TECHNOLOGIES INC−4.0%$35.9M
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | — Aridis Pharmaceuticals, Inc. | 13G | 11.4% · 2 classes | 5.1M | Filed 16 NOV 2026 |
| 2 | REKR Rekor Systems, Inc. | 13G | 10.0% | 14.1M | Filed 17 FEB 2026 |
| 3 | CTOR Citius Oncology, Inc. | 13G | 10.0% · 2 classes | 9.4M | Filed 16 NOV 2026 |
| 4 | TMCI TREACE MEDICAL CONCEPTS, INC. | 13G | 10.0% · 2 classes | 6.4M | Filed 17 FEB 2026 |
| 5 | — Li-Cycle Holdings Corp. | 13G | 10.0% · 2 classes | 4.6M | Filed 16 NOV 2026 |
| 6 | IINN INSPIRA TECHNOLOGIES OXY B.H.N. LTD. | 13G | 10.0% | 4.3M | Filed 15 MAY 2026 |
| 7 | CYAB Cyabra, Inc. | 13G | 10.0% | 3.9M | Filed 16 NOV 2026 |
| 8 | ALBT Change Agents Corporation | 13G | 10.0% | 1.6M | Filed 14 AUG 2026 |
| 9 | LTRN Lantern Pharma Inc. | 13G | 10.0% | 1.5M | Filed 16 NOV 2026 |
| 10 | GOVX GEOVAX LABS, INC. | 13G | 10.0% · 2 classes | 1.3M | Filed 16 NOV 2026 |
| 11 | CLDI CALIDI BIOTHERAPEUTICS, INC. | 13G | 10.0% | 1.1M | Filed 15 MAY 2026 |
| 12 | VRAX Virax Biolabs Group Ltd | 13G | 10.0% | 824K | Filed 17 FEB 2026 |
| 13 | QUCY MAINZ BIOMED N.V. | 13G | 10.0% | 723K | Filed 14 AUG 2025 |
| 14 | FBLG FibroBiologics, Inc. | 13G | 10.0% | 666K | Filed 16 NOV 2026 |
| 15 | WLDS Wearable Devices Ltd. | 13G | 10.0% · 2 classes | 620K | Filed 17 FEB 2026 |
| 16 | CODX CO-DIAGNOSTICS, INC. | 13G | 10.0% | 560K | Filed 14 AUG 2026 |
| 17 | EDBL Edible Garden AG Inc | 13G | 10.0% | 544K | Filed 17 FEB 2026 |
| 18 | CYTOF Altamira Therapeutics Ltd. | 13G | 10.0% | 474K | Filed 15 MAY 2025 |
| 19 | ENVB Enveric Biosciences, Inc. | 13G | 10.0% | 405K | Filed 14 AUG 2026 |
| 20 | — STRYVE FOODS, INC. | 13G | 10.0% · 2 classes | 397K | Filed 16 NOV 2026 |
| 21 | CYCU Cycurion, Inc. | 13G | 10.0% | 301K | Filed 17 FEB 2026 |
| 22 | BDRX Biodexa Pharmaceuticals Plc | 13G | 10.0% · 2 classes | 284K | Filed 17 FEB 2026 |
| 23 | HCWB HCW Biologics Inc. | 13G | 10.0% | 248K | Filed 16 NOV 2026 |
| 24 | BJDX Bluejay Diagnostics, Inc. | 13G | 10.0% · 2 classes | 194K | Filed 18 FEB 2026 |
| 25 | XAIR Beyond Air, Inc. | 13G | 10.0% | 173K | Filed 16 NOV 2026 |
Showing 1–25 of 46 disclosed stakes. 4 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading Armistice Capital, LLC’s 13F portfolio
Armistice Capital, LLC’s $3.6B 13F book is spread across 323 reported positions and is moderately diversified, the ten largest names accounting for 27%. There are meaningful positions at the top alongside a long tail of smaller holdings. Its five largest positions are MDGL, SUPN, CYTK, INCY and NBIX, led by MADRIGAL PHARMACEUTICALS INC (MDGL) at 4.3% of the portfolio. The heaviest sector exposure is Healthcare (68%), then Technology (15%).
What Armistice Capital, LLC changed last quarter
Between 2026-03-31 and Q2 2026, Armistice Capital, LLC was a net buyer: it opened 169 new positions and added to 70 more, while trimming 64 and closing 97 outright. Against a 323-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was MADRIGAL PHARMACEUTICALS INC (MDGL), and its biggest reduction was NEUROCRINE BIOSCIENCES INC (NBIX).
What a 13F does and doesn’t reveal
A 13F captures only Armistice Capital, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Armistice Capital, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Armistice Capital, LLC's profile on this page is built directly from those filings.
How current is the 13F data on Armistice Capital, LLC's page?
It reflects Armistice Capital, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Armistice Capital, LLC files its next quarterly report, this page refreshes automatically.
Can I see Armistice Capital, LLC's complete list of holdings?
This page highlights Armistice Capital, LLC's largest positions rather than all 323 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Armistice Capital, LLC's filings.
Does a 13F show everything Armistice Capital, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Armistice Capital, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Armistice Capital, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

